Shortly after its introduction, radiofrequency segmental thermal ablation (RSTA) became a technique used worldwide for heat-induced obliteration of incompetent great saphenous veins (GSVs). From the beginning, RSTA achieved immediate GSV ablation rates of Ͼ99% in addition to a very moderate side effect profile and a remarkably short average time interval for return to normal activity of Ͻ2 days. 1, 2 These findings have been corroborated recently, describing occlusion rates of 98% to 100% at 6 months of follow-up, further demonstrating that a vein diameter Ͼ12 mm is not related to a decreased ablation rate. 3 In addition, a prospective randomized trial proved that the side effect profile of RSTA compared favorably with endovenous laser ablation using a 980-nm diode laser and typical blunt-tipped bare fibers. 4 Because of the widespread use of RSTA, midterm results of the first clinical trial of RSTA, including the durability of once achieved GSV occlusions and the postinterventional course of clinical signs and scores, are of special interest. This report presents the 3-year update of the European RSTA Study Group with follow-up data retrieval from up to 86.4% of treated patients.
PATIENTS AND METHODS
Study design. Within a prospective, nonrandomized, multicenter cohort study, results at 36 months were obtained on safety data and clinical outcomes of RSTA of the GSV in otherwise unselected consecutive patients with clinically relevant chronic venous disease and GSV incompetence. Control visits, including duplex ultrasound (DUS) examination, were scheduled at 3 days and at 3, 6, 12, 24, and 36 months after the study treatment. Previous reports have described enrollment criteria, the study device, the treatment procedure and its evaluation protocol with patient follow-up, and also some feasibility data as well as early safety and clinical outcome data of parts of this cohort. 1,2 Study treatments were performed at eight clinical sites in Germany and France after approval by local authorities and local ethical review boards according to the Declaration of Helsinki and its later extensions.
Patient follow-up. Each follow-up visit consisted of a clinical examination, the completion of a questionnaire, and DUS examination of the treated leg in horizontal and reverse Trendelenburg position. Supine position for DUS examinations was preferred rather than standing to allow comparison with diameters obtained intraoperatively.
The primary study end points were occlusion of and lack of reflux in the treated vein. Vein occlusion was defined as absence of any blood flow along the entire length of the treated vein length determined by DUS imaging beginning from 3 cm distal to the saphenofemoral junction (SFJ) and continued from there. The 3-cm limit was selected because the occlusion status of the GSV proximal to this limit frequently had to be regarded nonspecific due to the variable entry-site of several tributaries. On the other hand, a precise measurement with a typical 4-cm length linear ultrasound probe is still possible. Secondary end points included the evaluation of side effects, adverse events, clinical outcomes, and patient recovery after the treatment.
Patient symptoms and signs were recorded using the CEAP clinical classification 5 and the Venous Clinical Severity Score (VCSS). 6 The side effects and complications associated with the procedure were recorded and analyzed. Postprocedural pain and tenderness, the latter represented the discomfort level in response to touch or palpation, were evaluated using an analog scale, with the minimum of 0 representing no pain and a maximum of 10 representing worst possible pain. The analog scale was used in a nonvisual fashion after explaining it to the patient.
Statistical methods. Baseline characteristics, including demographics, medical history, or venous symptoms were summarized using descriptive statistics. End point analysis was performed at the 2-year follow-up or longitudinally along distinct follow-up intervals if required. Measurable parameters were expressed as mean Ϯ standard deviation and proportions were expressed as percentage with a 95% confidence interval. Data were analyzed on a per-patient or a per-leg basis as appropriate for presentation of clinical data. Patients with bilateral treatment were treated as one for data analyzed on a per-subject basis. For data analyzed on a per-leg basis, the two legs were treated separately. If appropriate, for matched-pairs analysis only, those patients and legs were evaluated who completed the 3-year follow-up.
Kaplan-Meier analysis was used to describe recurrences of flow and reflux within treated veins. To protect across inferences and to preserve size of ␣, the type 1 error rate, the Tukey-Kramer honestly significant difference test was used to make multiple comparisons of means over time.
Contingency table analysis using likelihood ratio 2 statistics were used to test the hypothesis that the response rates were the same in each sample category. Continuity correction was applied, and exact P values were computed when cell sparseness rendered the analysis suspect. All analysis was performed using SAS 9.2 software (SAS Institute Inc, Cary, NC).
RESULTS
A total of 225 patients and 295 legs were treated from April 2006 to March 2007 at eight study centers in Germany and France. Patients with incompetent GSVs who met inclusion and exclusion criteria were offered treatment within this study. At the 3-year follow-up, 194 patients with 256 treated legs from seven centers were available, representing a proportion of 86.2% and 86.8% of the original study treatments, respectively. Thirty-one patients were not able to attend the 3-year follow-up, mainly because they moved to remote locations or because they declined further follow-up visits for personal reasons. Of 194 patients with follow-up at 3 years, 35.1% were treated at the center with the highest recruitment. Only two centers contributed Ͻ5% of the treated patients. Among the 256 treated legs monitored for 36 months, distribution was 127 right legs and 129 left legs, which was almost equal. The average treated length of the GSV from the SFJ to the site of vein access at the distal point of reflux was 36.8 Ϯ 10.5 cm. All RSTA interventions were performed under tumescent local anesthesia (TLA) with an average of 331 Ϯ 107 mL of TLA administered per treated GSV, corresponding to an average of 9.4 Ϯ 3.5 mL of TLA per cm of treated vein length.
Of the 256 legs available at the 3-year follow-up, 30 (11.7%) had undergone venous interventions previous to study treatment, however, not affecting the GSV. These included 3 vein strippings, 1 patient each with ligation, endovenous laser and phlebectomy, radiofrequency ablation, and radiofrequency ablation with concomitant sclerotherapy; 7 phlebectomies, 15 sclerotherapies, and 1 unspecified. Concomitantly with the study treatment, phlebectomy was performed in 147 of 256 legs (57.4%) and foam sclerotherapy of tributaries in 31 legs (12.1% ). An incompetent accessory anterior saphenous vein in one leg was treated with segmental thermal ablation immediately after study treatment. During the study follow-up of 36 months, 11 of 256 legs (4.3%) received additional treat-ments for persisting varicose tributaries, comprising phlebectomy in 1 and sclerotherapy in 10.
DUS examination of proximal vein diameter. Immediately after segmental thermal ablation, vein occlusion with absence of spontaneous and augmented flow was demonstrated by US examination in all but one leg, which showed delayed occlusion. Furthermore, vein wall thickening was evident immediately after treatment in 100% of the GSVs. Pretreatment vein diameters measured in supine position at 3 cm distal to the SFJ showed an average diameter of 5.8 Ϯ 2.1 mm (range, 2.0-14.0 mm). A pronounced shrinkage of the average diameter was visible already at 1 week after the procedure to 4.5 Ϯ 1.7 mm with a further reduction to 2.9 Ϯ 1.1 mm at 6 months, resembling 78% and 49% of the pretreatment diameter, respectively. Tukey-Kramer pair-wise analysis revealed statistically significant reductions (P Ͻ .05) in vein diameter when comparing baseline values with all follow-up values and when comparing diameters at 1 week and 3 months with diameters at 6, 12, 24, and 36 months.
DUS examination of nonoccluded stump lengths of the GSV. At the week 1 postprocedural follow-up, the mean nonoccluded stump lengths at the SFJ of 250 GSVs was 1.0 Ϯ 0.7 cm. No extension of the thrombus into the common femoral vein was observed Interestingly, the average nonoccluded stump lengths of the treated GSV did not change much during the 36-month follow-up. Corresponding values at 3, 6, 12, 24, and 36 months were 1.2 Ϯ 0.7, 1.2 Ϯ 0.7, 1.1 Ϯ 0.7, 1.1 Ϯ 0.7, and 1.2 Ϯ 0.7, respectively. Tukey-Kramer pair-wise analysis revealed a relevant difference only between the 1-week and 3-month follow-up (P Ͻ .05), indicating that increase of the nonoccluded stump lengths is not a natural process more than 3 months after the procedure.
Flow and reflux analysis. Blood flow and reflux were assessed by DUS examination along the treated vein from the SFJ toward the distal point of study treatment. Recurrence of any blood flow more distal than 3 cm from the SFJ, recurrence of any reflux, and recurrence of any axial reflux in the treated leg originating from the SFJ were described and plotted according to the Kaplan-Meier method.
At 3 days after study treatment, one vein exhibited flow with augmentation and showed reflux along the entire treated segment despite a narrowed lumen. This vein was occluded at the 3-month follow-up and at all later follow-up dates. Therefore, this GSV was judged to have delayed occlusion rather than reopening and was not included in the Kaplan-Meier analysis.
Recurrence of blood flow, reflux, and axial reflux. By DUS examination, blood flow in any part of the treated vein from 3 cm below the SFJ or more distally was observed during the 3-year follow-up in 21 GSVs. In reverse, no blood flow within the treated GSV was observed in 99.7%, 98.6%, 96.3%, 94.5%, and 92.6% at 3, 6, 12, 24, and 36 months. Standard error of the confounding Kaplan-Meier analysis (Fig 2, A) was Ͻ5% at all times. If a leg reached the 12-month follow-up visit without detection of flow, the chance to develop new flow during the consecutive 12 months was 3.7%. If a leg reached the 24-month follow-up visit without detection of flow, the chance to develop new flow during the consecutive 12 months was 4.1%.
Reflux of Ͼ500-ms duration in any part of the treated GSV was observed by DUS examination during the 3-year follow-up in 12 GSVs. No reflux within the treated GSV was observed in 99.7%, 99.3%, 99.0%, 97.2%, and 95.7% at 3, 6, 12, 24, and 36 months, respectively (Fig 2, B) . Standard error was Ͻ1% at all times. If occlusion of the treated GSV was observed at the 12-month follow-up, the risk that new reflux would develop during 24 months of follow-up was 2.9%. If occlusion of the treated GSV was observed at 24 months, the risk of developing new reflux during 24 months of follow-up was 3.3%.
Axial reflux as defined recently, 7 originating at the SFJ and conducted within the initially occluded GSV or by different parallel pathways down to the calf region, was observed during the 3-year follow-up in only five GSVs. As reported in more detail in Table I , 7 only two cases resulted from full recanalization of the RSTA-treated GSV, one at 6 months and another after 36 months. In two legs the accessory anterior saphenous vein was involved as the route of axial reflux, and in one instance carrying the reflux to the distal thigh and entering the GSV at a point where no study treatment was applied before due to a lack of incompetency at the time of study treatment. In the second leg with involvement of the accessory anterior saphenous vein, the axial reflux was conducted through the GSV stump for Ͻ3 cm, then transferred to the proximal competent accessory anterior saphenous vein. In the last leg, after a 6-cm recanalization, reflux was conducted down to the calf through a ventral thigh tributary.
Clinical response to study treatment: CEAP. We are well aware that the CEAP classification originally was not designed to monitor treatment results. In this study, however, the clinical part of CEAP was used for the restaging of patients in yearly intervals and showed quite interesting results.
The pretreatment maximum CEAP clinical class distribution is summarized in Table II , showing 85.5% of legs had a pretreatment CEAP class of ՅC 3 , with C 2 alone in 52.3%. In general, all 256 legs that were available at the 36-month follow-up were in CEAP classes C 1 to C 4 before study treatment, except one leg in stage C 6 . However, because clinical stage C 6 is not fully reversible, contingency analysis, as displayed in Fig 3, A, was limited to clinical stages C 0 to C 4 . Of these 255 legs assessed at 36 months, 189 (74.1%) showed an improvement in CEAP class if compared with the clinical assessment before the study treatment (P Ͻ .001). No change of CEAP class was observed in 64 legs (25.1%), whereas CEAP class worsened in only 2 legs (Ͻ1%).
Remarkably, the proportion of legs in clinical stages of C 2 , C 3 , or C 4 dropped from 99% to Ͻ20% during the first year of follow-up and increased slightly to 30% at 2 years and to 41% at 3 years. However, the more severe clinical stages C 3 and C 4 with 46% of legs before treatment showed an ongoing improvement during follow-up reaching a proportion of finally 7% at 2 years and 8% at 3 years. Fig 3, B displays the most relevant CEAP stages C 2 to C 4 more clearly. It seems noticeable that the proportion of legs in clinical stage C 2 , after a drop from 52.3% before treatment to Ͻ10% immediately thereafter was increasing again slowly toward the 2-year follow-up to a value of Ͼ20% and to 33.3% at 3 years. The proportion of legs in clinical stage C 4 , however, showed an ongoing constant drop from 14.1% before study treatment to almost 3% at the 2-year follow-up and 4% at the 3-year follow-up.
Clinical response to study treatment: VCSS. At baseline, the average VCSS of 256 legs monitored for 36 months was 3.9 Ϯ 2.1. The minimum VCSS observed at study entry was 1, representing the sole presence of varicose veins or venous edema with ankle swelling in the evening. The maximum baseline VCSS was 11 in three patients, one of whom was a man classified C 6 according to CEAP. This patient presented with an medial ankle ulceration of Ͻ2-cm diameter until the 3-month follow-up but showed no more ulceration from 6 months of follow-up on. The time course of VCSS along follow-up is displayed in Fig 4. Interestingly, the drop of VCSS after study treatment, but even more between 1 week and 3 months, was maintained throughout the entire follow-up period. The average VCSS score improved to 3.5 Ϯ 1.1 at 1 week and to 0.9 Ϯ 1.5 at the 3-month follow-up. Average VCSS stayed Ͻ0.7 up to 24 months but increased slightly to 0.9 at 36 months. However, the average reduction in VCSS scores from screening and at 1 week to 3, 6, 12, 24, and 36 months were statistically significant at the .05 level, as revealed by Tukey-Kramer analysis.
Interestingly, before treatment, only 41.1% of patients were free of pain in the treated leg, at 36 months, 251 legs (98.0%) were reported free of pain, and 245 (95.7%) did not experience pain in the treated leg during the 24 months before.
Side effects. Side effects in generally were mild and occurred with a low frequency, as listed in Table III . Remarkably at 36 months, only 1 of 256 legs showed hyperpigmentation over the course of the treated GSV, and only 1 patient complained of persisting paresthesia in an area attributable to the saphenous nerve. No more side effects were detected at 3 months of follow-up or afterward and generally occurred with a low frequency.
DISCUSSION
Segmental thermal ablation has already been proven to be a highly efficient and fast procedure for GSV ablation. 1 Now, 3-year follow-up showed that the high ablation rates JOURNAL OF VASCULAR SURGERY Volume ⅢⅢ, Number Ⅲ obtained initially could not only be maintained but could also transfer into durable clinical benefits in VCSS and clinical CEAP stage. In only 4.3% of treated GSVs was new reflux detected by DUS imaging, and only 2.0% of treated legs revealed new axial reflux with 86.4% of treated legs examined at the 3-year follow-up.
The occlusion rate seems to be much better than the one described for the preceding method with Closure PLUS (VNUS Technologies). 8 However, RSTA seemed to preserve the favorable side effect profile despite delivering linear energy densities 9 of Ͼ120 J/cm during the first treatment cycle and Ͼ70 J/cm thereafter. These energy doses compare with current recommendations for endovenous laser treatment of the GSV but elicited fewer side effects in a prospective randomized multicenter trial against 980-nm laser treatment using bare fibers. 4 In particular, pain, tenderness, and ecchymosis were less frequent in the segmental thermal ablation group during the first 2 weeks after the procedure. These findings were corroborated by a recent observational study comparing segmental thermal ablation with 980-nm laser ablation. 10 A paresthesia frequency of 0.4% in our study compares favorably with 1470-nm endovenous laser ablation showing a paresthesia rate of 7.6% at 12 months after treatment. Heat-induced shrinkage of the GSV diameter, a surrogate marker for the delivery of a sufficient dose of thermal energy during endovenous ablation, 3 cm below the SFJ showed a value of 78% at 1 week after segmental thermal ablation. A representative report on typical endovenous laser ablation described shrinkage of 66% after 6 weeks. 12 Apart from shrinkage, we focused on the nonoccluded stump length of the GSV after segmental thermal ablation serving as a natural sinus to collect venous blood from the area and also preventing thrombus extension during the initial phase after endothermal GSV ablation. In our study, the nonoccluded stump length was at an average that was constant during the complete follow-up time of 36 months, varying only slightly from 10 to 12 mm, suggesting that an increasing stump length during follow-up is not a normal phenomenon, but instead may indicate proximal recanalization.
Even if the focus of today is on reduction of treatmentrelated side effects and reduction of periprocedural impairment of patients' quality of life, one still has to remember that the primary treatment goal is ablation of pathologic refluxes in incompetent saphenous veins. Side effect reduction by delivery of lower energy doses seems easy; however, concomitant reduction of ablation rates may be a logic consequence, as in a recent report on 1500-nm laser ablation with a delivered endovenous energy of only 53.4 J/cm and an occlusion rate that dropped to 93.3% by 6 months of follow-up. 13 Segmental thermal ablation actually provides high ablation rates (Fig 2) in conjunction with a very moderate side effect profile. Such high ablation rates can even be achieved by RSTA with vein diameters Ͼ12 mm. 3 In our study, only 5 of 256 legs (2.0%) presented with recurrent axial reflux.
Outcome measurement in treatment of venous disorders cannot only rely on DUS evaluation of ablated saphenous veins, even though it is a necessary condition for the improvement of the patient's clinical condition. At the time when this study was designed, scores on instruments for measurement of quality of life, such as the Medical Outcomes Study Short Form 36 Health Survey 14 and the Chronic Venous Insufficiency Quality of Life Questionnaire (CIVIQ), 15 appeared not as mandatory as they are today and were not included in the protocol of this study.
Instead, clinical classification according to CEAP 5 and the VCSS 6 were used to re-evaluate patients at any given follow-up interval, even though neither instrument was designed for measurement of treatment-related outcomes in early clinical stages of venous disease. Before treatment, VCSS averaged about 5 (range 2-12), indicating moderate venous disease in our patients. However, statistics were able to show improvement of the VCSS to baseline Յ3 months after study treatment and, furthermore, that our patients maintained this level throughout the 36-month follow-up (Fig 4) .
CEAP is a detailed descriptive tool for classification of venous disease but originally was not designed for measurement of treatment success during follow-up. Interestingly, the prevalence of skin changes (C 4 ) in our study dropped from about 15% at screening to 4% at 36 months. Edema (C 3 ) disappeared almost instantly after study treatment and did not recur during 36 months of follow-up in a relevant proportion of patients. Varicose veins (C 2 ) were not completely eliminated, because treatment of thigh-level tributaries was not allowed by the study protocol. However, after achieving a reduction of C 2 to 10% to 15% during the first year of follow-up, an increase to Ͼ30% was noticeable at the 3-year follow-up, suggesting a risk of around 10% per year to develop new C 2 -varicosities in a treated leg. This may reflect the natural course of the disease; however, the numbers reported in a case-control study over 5 years were only 17% during the entire study period. 16 In our study, however, it remains unclear if this higher number of new C 2 varicosities could be related to untreated thigh varicosities, as requested by the study protocol, to avoid overlap in treatment-related symptoms to the study procedure.
CONCLUSIONS
The 3-year follow-up after segmental thermal ablation proves endured maintenance of an initially achieved ablation rate of 100%, with only 2.0% of axial reflux during the study follow-up of 36 months. This successful ablation is achieved with a very moderate side effect profile and is further connected to an improvement in CEAP class grading and VCSS. This highly effective treatment should be compared with other modalities for treatment of incompetent GSVs in prospective randomized trials. 
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